NASDAQ: GDRXGoodrx Holdings Inc Stock
$6.96-0.01 (-0.14%)
Updated Apr 24, 2024
GDRX Price
$6.96
Fair Value Price
$7.06
Market Cap
$2.75B
52 Week Low
$4.14
52 Week High
$9.37
P/E
-348x
P/B
3.61x
P/S
3.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$750.27M
Earnings
-$8.87M
Gross Margin
91.1%
Operating Margin
0.15%
Profit Margin
-1.2%
Debt to Equity
1.09
Operating Cash Flow
$138M
Beta
1.95
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GDRX Overview
GoodRx Holdings, Inc. operates a telemedicine platform. It alos offers a website/mobile app that tracks prescription drug prices in the U.S. and provides coupons for discounts on medications. Its telemedicine platform, GoodRx Care, allows individuals to consult with a doctor online and obtain a prescription for certain types of medications as well as obtain referrals for medical testing. GoodRx was founded in 2011 and is headquartered in Santa Monica, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GDRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GDRX ($6.96) is undervalued by 1.46% relative to our estimate of its Fair Value price of $7.06 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GDRX ($6.96) is not significantly undervalued (1.46%) relative to our estimate of its Fair Value price of $7.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GDRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GDRX due diligence checks available for Premium users.
Be the first to know about important GDRX news, forecast changes, insider trades & much more!
GDRX News
Valuation
GDRX fair value
Fair Value of GDRX stock based on Discounted Cash Flow (DCF)
Price
$6.96
Fair Value
$7.06
Undervalued by
1.46%
GDRX ($6.96) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GDRX ($6.96) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GDRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GDRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-348x
Industry
72.14x
Market
41.27x
GDRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.61x
Industry
3.39x
GDRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GDRX's financial health
Profit margin
Revenue
$196.6M
Net Income
-$25.9M
Profit Margin
-13.2%
GDRX's Earnings (EBIT) of $1.16M... subscribe to Premium to read more.
Interest Coverage Financials
GDRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$826.8M
Debt to equity
1.09
GDRX's short-term assets ($872.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GDRX's short-term assets ($872.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GDRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GDRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.9M
Investing
-$12.9M
Financing
-$125.6M
GDRX's operating cash flow ($138.29M)... subscribe to Premium to read more.
Debt Coverage Financials
GDRX vs Health Information Service Stocks
Goodrx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.